Literature DB >> 8348746

IL-2 enhances polyclonal IgM but not IgM-rheumatoid factor synthesis by activated human peripheral blood B cells.

M Callaghan1, A Whelan, C Feighery, B Bresnihan.   

Abstract

IgM-rheumatoid factor (RF) is thought to be involved in the pathogenesis of rheumatoid arthritis (RA). Several cytokines are known to regulate immunoglobulin synthesis. In this study the effects of IL-2 on polyclonal IgM and IgM RF synthesis were compared. Cytokines were added to peripheral blood B cells from normal subjects and patients with RA after activation by Staphylococcus aureus Cowan 1 (SAC). The addition of IL-2, but not IL-4 or IL-6, resulted in significant enhancement of IgM synthesis in cultures from both healthy subjects and patients with RA. Similar degrees of enhancement were seen in both peripheral blood mononuclear cell and highly purified B cell cultures. IgM-RF was synthesized after activation in cultures from healthy subjects and spontaneously in cultures from RA patients. In contrast to polyclonal IgM synthesis, IL-2 failed to augment IgM-RF synthesis in cell cultures from either healthy subjects or RA patients. This study demonstrates different effects of IL-2 on IgM and IgM-RF synthesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8348746      PMCID: PMC1554842          DOI: 10.1111/j.1365-2249.1993.tb07968.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  52 in total

1.  Effect of recombinant IL 2 and gamma-IFN on proliferation and differentiation of human B cells.

Authors:  T Nakagawa; T Hirano; N Nakagawa; K Yoshizaki; T Kishimoto
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

2.  Activated human B cells display a functional IL 2 receptor.

Authors:  R Mittler; P Rao; G Olini; E Westberg; W Newman; M Hoffmann; G Goldstein
Journal:  J Immunol       Date:  1985-04       Impact factor: 5.422

3.  Analysis of the role of interferon-gamma, interleukin 2 and a third factor distinct from interferon-gamma and interleukin 2 in human B cell proliferation. Evidence that they act at different times after B cell activation.

Authors:  S Romagnani; G M Giudizi; F Almerigogna; R Biagiotti; A Alessi; C Mingari; C M Liang; L Moretta; M Ricci
Journal:  Eur J Immunol       Date:  1986-06       Impact factor: 5.532

4.  Structural and functional characterization of IL 2 receptors on activated human B cells.

Authors:  A W Boyd; D C Fisher; D A Fox; S F Schlossman; L M Nadler
Journal:  J Immunol       Date:  1985-04       Impact factor: 5.422

5.  Interleukin 2 receptors on human B cells. Implications for the role of interleukin 2 in human B cell function.

Authors:  A Muraguchi; J H Kehrl; D L Longo; D J Volkman; K A Smith; A S Fauci
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

6.  Both interleukin 2 and a second T cell-derived factor in EL-4 supernatant have activity as differentiation factors in IgM synthesis.

Authors:  K Nakanishi; T R Malek; K A Smith; T Hamaoka; E M Shevach; W E Paul
Journal:  J Exp Med       Date:  1984-12-01       Impact factor: 14.307

7.  Lymphoid irradiation in intractable rheumatoid arthritis: effects on the production of immunoglobulins and rheumatoid factors.

Authors:  J G Hanly; J Hassan; M Moriarty; A Whelan; C Feighery; B Bresnihan
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

8.  Effect of total lymphoid irradiation on levels of serum autoantibodies in systemic lupus erythematosus and in rheumatoid arthritis.

Authors:  A Tanay; G Schiffman; S Strober
Journal:  Arthritis Rheum       Date:  1986-01

9.  Effects of gold therapy on the synthesis and quantity of serum and synovial fluid IgM, IgG, and IgA rheumatoid factors in rheumatoid arthritis patients.

Authors:  J G Hanly; J Hassan; A Whelan; C Feighery; B Bresnihan
Journal:  Arthritis Rheum       Date:  1986-04

10.  Expression of interleukin 2 receptors on activated human B cells.

Authors:  T A Waldmann; C K Goldman; R J Robb; J M Depper; W J Leonard; S O Sharrow; K F Bongiovanni; S J Korsmeyer; W C Greene
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.